Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: Acute ischemic stroke (AIS): An overview • Ischemia • IHD • Stroke • AIS PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation by drug-class • Thrombolytic therapeutics • Antihypertensive therapeutics • Antiplatelet therapeutics • Anticoagulants • Others PART 09: Geographical segmentation • Market overview based on geography • AIS therapeutics market in Americas • AIS therapeutics market in EMEA • AIS therapeutics market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • TBI, a value-addition in AIS research • Advent of genomic medicine PART 13: Vendor landscape • Competitive scenario • Key news PART 14: Key vendor analysis • Bayer • Boehringer Ingelheim • F. Hoffmann-La Roche • Sanofi • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Symptoms of AIS Exhibit 02: Global AIS therapeutics market: Snapshot Exhibit 03: Global AIS therapeutics market 2016-2021 ($ millions) Exhibit 04: Mechanism of action of alteplase Exhibit 05: Global AIS therapeutics market: Opportunity analysis Exhibit 06: Five forces analysis Exhibit 07: Pipeline snapshot Exhibit 08: Key clinical trials Exhibit 09: Global AIS therapeutics market segmentation by drug-class Exhibit 10: Global AIS therapeutics market share by drug-class 2016 Exhibit 11: Global AIS thrombolytic therapeutics market 2016-2021 ($ millions) Exhibit 12: Global AIS antihypertensive therapeutics market 2016-2021 ($ millions) Exhibit 13: Global AIS antiplatelet therapeutics market 2016-2021 ($ millions) Exhibit 14: Global AIS anticoagulant therapeutics market 2016-2021 ($ millions) Exhibit 15: Global AIS therapeutics market share by geography 2016 and 2021 Exhibit 16: Global AIS therapeutics market by geography 2016-2021 ($ millions) Exhibit 17: Global AIS therapeutics market by geography 2016-2021 (% share) Exhibit 18: AIS therapeutics market scenario in different geographies Exhibit 19: Market scenario in Americas Exhibit 20: Stroke scenario in US: An overview Exhibit 21: AIS therapeutics market in Americas 2016-2021 ($ millions) Exhibit 22: Market scenario in EMEA Exhibit 23: AIS therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 24: Market scenario in APAC Exhibit 25: AIS therapeutics market in APAC 2016-2021 ($ millions) Exhibit 26: Prevalence of stroke in US Exhibit 27: ACTIVASE regional sales 2015 and 2016 Exhibit 28: Prevalence of obesity among US adults in 2015 Exhibit 29: Competitive structure analysis of global AIS therapeutics market 2016 Exhibit 30: Bayer: Key highlights Exhibit 31: Bayer: Strength assessment Exhibit 32: Bayer: Strategy assessment Exhibit 33: Bayer: Opportunity assessment Exhibit 34: Boehringer Ingelheim: Key highlights Exhibit 35: Boehringer Ingelheim: Strength assessment Exhibit 36: Boehringer Ingelheim: Strategy assessment Exhibit 37: Boehringer Ingelheim: Opportunity assessment Exhibit 38: F. Hoffmann-La Roche: Key highlights Exhibit 39: F. Hoffmann-La Roche: Strength assessment Exhibit 40: F. Hoffmann-La Roche: Strategy assessment Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment Exhibit 42: Sanofi: Key highlights Exhibit 43: Sanofi: Strength assessment Exhibit 44: Sanofi: Strategy assessment Exhibit 45: Sanofi: Opportunity assessment

Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche, Sanofi, Biogen, Daiichi Sankyo, and Pfizer.